Pfizer
and AstraZeneca are known as two of the biggest companies in the pharmaceutical
industry. PFE have been trying a lot to join hands with AstraZeneca in
recent times but it has failed to do so in a couple of events. AstraZeneca,
being one of the top names, are reluctant to merge with Pfizer in the near
future.
The
spokesperson of the company, Joan Campion told that the company is looking for
every available option. She further added that the company is “evaluate all
opportunities, regardless of size, through the lens of value creation for our
shareholders and enhancing the competitiveness of our business.” And because of
Actavis' recent buying spree, it's worth some $59 billion--large enough to
allow Pfizer to shift its domicile to Dublin.” So Actavis will be bolstering a
large portfolio of the company by bringing high profile brand names along with
newly approved drugs and medicines as well.
Bloomberg
reports that “an Actavis buy would build up Pfizer's established products unit,
widely seen as the first prospect for another sale or spin-off. It would add
some new products to Pfizer's branded stable, which is in need of help.
As
recently, AstraZeneca has raised the bar by increasing its profits and revenues
in 2014, it is expected that the company will raise its asking price. There are
many analysts who believe that Pfizer is wasting its time in this deal. They
are sure that this deal, which can be one of the biggest mergers in the
pharmaceutical industry, can and will never go through. Being one of the
biggest names, AstraZeneca is too expensive for Pfizer at the moment. Either
AstraZeneca are not content with the offer or Pfizer do not really have a great
shot at buying AstraZeneca at the moment. Whatsoever be the reason, Pfizer is
ready to give it another try as the company eyes Actavis in backup plan to
another AstraZeneca bid.
No comments:
Post a Comment